Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.36 |
| ▸ | NPM1 | P06748 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4541479 | 1.00 | HTT (0.50) | HTTCYP1A2CYP2C19PTGESBACE1 | |
| SCHEMBL31468230 | 0.84 | MALT1 (0.42) | HTTCYP1A2CYP2C19PTGESBACE1 | |
| SCHEMBL7157574 | 0.81 | PDGFRB (0.59) | CYP1A2PDGFRBPDGFRANOS1DYRK1A | |
| SCHEMBL30702581 | 0.81 | PDGFRB (0.59) | CYP1A2PDGFRBPDGFRANOS1DYRK1A | |
| SCHEMBL10688343 | 0.76 | PDGFRB (0.54) | HTTCYP1A2CYP2C19BACE1PDGFRB | |
| SCHEMBL14908778 | 0.76 | HTT (0.54) | HTTPDGFRBPDGFRAKDRNPC1 | |
| SCHEMBL4534377 | 0.76 | CYP1A2 (0.50) | HTTCYP1A2CYP2C19PTGESBACE1 | |
| SCHEMBL18554573 | 0.76 | ESR2 (0.59) | PDGFRBPDGFRANR4A2 | |
| SCHEMBL4539841 | 0.76 | KDM4E (0.52) | HTTCYP1A2CYP2C19BACE1NOS1 | |
| SCHEMBL8268977 | 0.76 | ALDH1A1 (0.50) | CYP1A2BACE1PDGFRBPDGFRAPABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145961-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-19 | — | — | US | disclosed |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-30 | — | — | US | disclosed |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-28 | — | — | US | disclosed |
| US-11702441-B2 | Spirobicyclic analogues | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | HTT 3019/4885CYP1A2 3501/4885CYP2C19 4303/4885 |
| US-20230071711-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | HTT 3861/4885CYP1A2 2522/4885CYP2C19 2305/4885 |
| US-11883367-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | HTT 3943/4885CYP1A2 2244/4885CYP2C19 1987/4885 |
| US-20230303612-A1 | Novel Spirobicyclic Analogues | PRMT5, SIRT5, HDAC5 | HTT 4633/4885CYP1A2 3177/4885CYP2C19 3040/4885 |
| US-11702441-B2 | Spirobicyclic analogues | PRMT5, HDAC5, SIRT5 | HTT 4558/4885CYP1A2 2874/4885CYP2C19 3100/4885 |
| US-12145961-B2 | Spirobicyclic analogues | PRMT5, HDAC5, SIRT5 | HTT 4558/4885CYP1A2 2874/4885CYP2C19 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.